COVID Funding: White House Pleads For Emergency Extension As ‘Runway’ To Commercial Market
Biden administration warns that additional oral antivirals may not be purchased if Congress does not provide $22.5bn emergency funding for COVID response, imperiling the new Test to Treat initiative and other programs.
You may also be interested in...
Drug developers discuss transitioning the pricing and purchasing of their COVID treatments to the private market during an advisory panel meeting hosted by the Institute for Clinical and Economic Review.
Lobbyists discuss what will happen with the healthcare agenda if Republicans retake the House in the mid-term elections and the prospects for passing a prescription drug pricing bill before then.
Community pharmacists say widespread implementation of Biden’s rapid pill dispensing initiative necessitates allowing pharmacists to prescribe Paxlovid and molnupiravir. But AMA worries that even clinic-based prescribing puts patients at risk because it bypasses primary care doctors.